G Procopio

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients
    Pamela Biondani
    Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori Via Venezian 1, 20133 Milan, Italy
    Anticancer Res 34:2395-8. 2014
  2. ncbi request reprint Treatment of collecting duct carcinoma: current status and future perspectives
    Giuseppe Procopio
    Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133, Milan, Italy
    Anticancer Res 34:1027-30. 2014
  3. pmc Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
    G Procopio
    Department of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Br J Cancer 108:311-8. 2013
  4. pmc Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
    G Procopio
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Br J Cancer 107:1227-32. 2012
  5. doi request reprint Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma
    Giuseppe Procopio
    Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Veneziani 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 12:1089-96. 2012
  6. doi request reprint Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases
    Giuseppe Procopio
    Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy
    Clin Exp Nephrol 16:464-7. 2012
  7. doi request reprint Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience
    Giuseppe Procopio
    Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology, Via G Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 11:1631-40. 2011
  8. pmc Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
    G Procopio
    Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian, Milan 1 20133, Italy
    Br J Cancer 104:1256-61. 2011
  9. doi request reprint Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors
    Giuseppe Procopio
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Neurol Sci 32:S217-9. 2011
  10. doi request reprint Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration
    Giuseppe Procopio
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy
    BJU Int 108:223-7. 2011

Detail Information

Publications20

  1. ncbi request reprint Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients
    Pamela Biondani
    Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori Via Venezian 1, 20133 Milan, Italy
    Anticancer Res 34:2395-8. 2014
    ..This retrospective study investigated the efficacy of the sequence sorafenib-sunitinib (SO-SU) and vice versa (SU-SO) in a real-life scenario...
  2. ncbi request reprint Treatment of collecting duct carcinoma: current status and future perspectives
    Giuseppe Procopio
    Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133, Milan, Italy
    Anticancer Res 34:1027-30. 2014
    ..Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting. The present study evaluated the activity of targeted therapies in metastatic CDC...
  3. pmc Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
    G Procopio
    Department of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Br J Cancer 108:311-8. 2013
    ..Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (<55, 55-<65, 65-<75, or ≥ 75 years)...
  4. pmc Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
    G Procopio
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Br J Cancer 107:1227-32. 2012
    ..The most important prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) were evaluated in the era of cytokine therapy, and only recently were revalidating in patients receiving targeted therapies (TTs)...
  5. doi request reprint Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma
    Giuseppe Procopio
    Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Veneziani 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 12:1089-96. 2012
    ....
  6. doi request reprint Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases
    Giuseppe Procopio
    Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy
    Clin Exp Nephrol 16:464-7. 2012
    ..Few data so far available concern the subgroup analyses from the expanded access programs with sorafenib and sunitinib, and from temsirolimus randomized study...
  7. doi request reprint Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience
    Giuseppe Procopio
    Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology, Via G Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 11:1631-40. 2011
    ..These findings support the use of targeted therapies in the treatment of RCC, even in a large unselected population from a single institution, and suggest that treatment should be tailored to meet individual circumstances and needs...
  8. pmc Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
    G Procopio
    Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian, Milan 1 20133, Italy
    Br J Cancer 104:1256-61. 2011
    ..Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC)...
  9. doi request reprint Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors
    Giuseppe Procopio
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Neurol Sci 32:S217-9. 2011
    ....
  10. doi request reprint Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration
    Giuseppe Procopio
    Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy
    BJU Int 108:223-7. 2011
    ..To assess the efficacy of ketoconazole in patients with castration-resistant prostate cancer (CRPC)...
  11. doi request reprint Role of sorafenib in renal cell carcinoma: focus on elderly patients
    Giuseppe Procopio
    Fondazione Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 11:1689-92. 2011
    ..This article will discuss the current role of sorafenib in the treatment of elderly patients with renal cell carcinoma...
  12. ncbi request reprint Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
    G Procopio
    Department of Medical Oncology, Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
    Ann Oncol 24:2967-71. 2013
    ..Updated overall survival (OS) results are reported...
  13. ncbi request reprint Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
    E Bajetta
    Medical Oncology Unit 2, ITMO Group, Nuclear Medicine, Department of Statistics, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
    Ann Oncol 16:1374-80. 2005
    ..The aim of this trial was to apply the new classification criteria in clinical practice and, accordingly, to choose the most appropriate treatment...
  14. ncbi request reprint Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours
    E Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano, Italy
    Ann Oncol 13:614-21. 2002
    ..The present study aimed to assess in a multidisciplinary manner the efficacy of the same regimen at intensified doses in patients with advanced NETs...
  15. pmc Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  16. ncbi request reprint Advances in diagnosis and therapy of neuroendocrine tumors
    E Bajetta
    Operative Unit of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 1:371-81. 2001
    ..Chemotherapy is the best choice in the treatment of neuroendocrine tumors characterized by a poor differentiation grade and a high proliferation rate...
  17. ncbi request reprint [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]
    E Bombardieri
    Unità Operativa Medicina Nucleare, Istituto Nazionale Tumori Milano, Milan, Italy
    Minerva Endocrinol 26:197-213. 2001
    ..Aim of this review is to summarize the potential of nuclear medicine techniques in the diagnosis of neuroendocrine tumours and to stresses the renewed role of nuclear medicine in the management of this disease...
  18. ncbi request reprint Fluoropyrimidines in the treatment of advanced neoplastic diseases: role and advantages of UFT
    M del Vecchio
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 85:6-11. 1999
    ..Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally...
  19. ncbi request reprint Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors
    L Ferrari
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Biol Markers 19:295-304. 2004
    ..This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA...